1. SAT0245 Azd9567: a novel oral selective glucocorticoid receptor modulator, demonstrated to have an improved therapeutic ratio compared to prednisolone in pre-clinical studies, is safe and well tolerated in first clinical study. (12th June 2018) Authors: Hendrickx, R.; Hegelund-Myrbäck, T.; Dearman, M.; Prothon, S.; Edenro, G.; Leander, J.; Fuhr, R.; Körnicke, T.; Svanberg, P.; Berggren, A. R.; Drmota, T.; Keen, C.; Eriksson, U. G. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0251 Selective glucocorticoid receptor modulator shows potent anti-inflammatory effect with improved metabolic profile in a phase i study supported by in vitro data. (12th June 2018) Authors: Hegelund Myrbäck, T.; Prothon, S.; Dearman, M.; Edenro, G.; Leander, J.; Hashemi, M.; de Miquel, G.; Fuhr, R.; Körnicke, T.; Tahib, Z.; Andersson, E.-M.; Svanberg, P.; Edman, K.; Hendrickx, R.; Keen, C.; Kraan, M.; Johansson, K.; Eriksson, U. G.; Carlsson, B.; Vaarala, O. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 987 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗